|Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL|
JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ...
New England Journal of Medicine, 2018
|BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia|
JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ...
Journal of Clinical Oncology 35 (13), 1437, 2017
|Expression and prognostic impact of lncRNAs in acute myeloid leukemia|
R Garzon, S Volinia, D Papaioannou, D Nicolet, J Kohlschmidt, PS Yan, ...
Proceedings of the National Academy of Sciences 111 (52), 18679-18684, 2014
|Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia|
MR Grever, O Abdel-Wahab, LA Andritsos, V Banerji, J Barrientos, ...
Blood, The Journal of the American Society of Hematology 129 (5), 553-560, 2017
|Targeting PI 3‐kinase (PI 3 K), AKT and m TOR axis in lymphoma|
JS Blachly, RA Baiocchi
British journal of haematology 167 (1), 19-32, 2014
|Emerging drug profile: cyclin-dependent kinase inhibitors|
JS Blachly, JC Byrd
Leukemia & lymphoma 54 (10), 2133-2143, 2013
|BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor|
HG Ozer, D El-Gamal, B Powell, ZA Hing, JS Blachly, B Harrington, ...
Cancer discovery 8 (4), 458-477, 2018
|Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia|
B Bhatnagar, AK Eisfeld, D Nicolet, K Mrózek, JS Blachly, S Orwick, ...
British journal of haematology 175 (2), 226-236, 2016
|HDAC inhibition induces microRNA-182, which targets RAD51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia|
TH Lai, B Ewald, A Zecevic, C Liu, M Sulda, D Papaioannou, R Garzon, ...
Clinical cancer research 22 (14), 3537-3549, 2016
|Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies|
AK Eisfeld, J Kohlschmidt, K Mrózek, JS Blachly, CJ Walker, D Nicolet, ...
Leukemia 32 (6), 1338-1348, 2018
|PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL|
D El-Gamal, K Williams, TD LaFollette, M Cannon, JS Blachly, Y Zhong, ...
Blood 124 (9), 1481-1491, 2014
|Quality Control for RNA-Seq (QuaCRS): an integrated quality control pipeline|
KW Kroll, NE Mokaram, AR Pelletier, DE Frankhouser, MS Westphal, ...
Cancer informatics 13, CIN. S14022, 2014
|The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia|
AK Eisfeld, K Mrózek, J Kohlschmidt, D Nicolet, S Orwick, CJ Walker, ...
Leukemia 31 (10), 2211-2218, 2017
|Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia|
JS Blachly, AS Ruppert, W Zhao, S Long, J Flynn, I Flinn, J Jones, ...
Proceedings of the National Academy of Sciences 112 (14), 4322-4327, 2015
|EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia|
E Young, D Noerenberg, L Mansouri, V Ljungström, M Frick, LA Sutton, ...
Leukemia 31 (7), 1547-1554, 2017
|Hairy cell leukemia: update on molecular profiling and therapeutic advances|
MR Grever, JS Blachly, LA Andritsos
Blood reviews 28 (5), 197-203, 2014
|Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t (8; 21)(q22; q22) acute myeloid leukemia|
AK Eisfeld, J Kohlschmidt, S Schwind, D Nicolet, JS Blachly, S Orwick, ...
Leukemia 31 (6), 1278-1285, 2017
|Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center|
KA Rogers, M Luay, Q Zhao, T Wiczer, L Levine, EB Zeinab, JS Blachly, ...
Blood 130 (Supplement 1), 830-830, 2017
|Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib|
JS Blachly, G Lozanski, DM Lucas, MR Grever, K Kendra, LA Andritsos
Journal of the National Comprehensive Cancer Network 13 (1), 9-13, 2015
|Targeting BTK through microRNA in chronic lymphocytic leukemia|
A Bottoni, L Rizzotto, TH Lai, C Liu, LL Smith, R Mantel, S Reiff, ...
Blood, The Journal of the American Society of Hematology 128 (26), 3101-3112, 2016